At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PHAT Phathom Pharmaceuticals
Trading 07-20 14:10:58 EDT
10.75
-0.19
-1.74%
High11.22Low10.68Vol304.17K
Open10.90D1 Closing10.94Amplitude4.97%
Mkt Cap853.87MTradable Cap674.90MTotal Shares79.43M
T/O3.28MT/O Rate0.48%Tradable Shares62.78M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Phathom Pharma Schedules Second-quarter Earnings Webcast
Reuters  ·  07-20 20:02
Phathom Pharma Schedules Second-quarter Earnings Webcast
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
GlobeNewswire  ·  07-20 20:00
Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026
Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
TIPRANKS  ·  06-25
Analysts Conflicted on These Healthcare Names: Phathom Pharmaceuticals (PHAT) and Elicio Therapeutics (ELTX)
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
TIPRANKS  ·  06-23
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
MT Newswires Live  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment for Phase 2 Trial of Voquezna
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Reuters  ·  06-23
Phathom completes enrollment in Phase 2 VOQUEZNA trial for eosinophilic esophagitis in adults
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
THOMSON REUTERS  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 Phalcon-Eoe-201 Study of Voquezna® (Vonoprazan) in Eosinophilic Esophagitis (Eoe)
Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026
THOMSON REUTERS  ·  06-23
Phathom Pharmaceuticals - Topline Results From Phase 2 Trial Expected in Q4 2026
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
GlobeNewswire  ·  06-23
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TIPRANKS  ·  06-17
Wall Street Analysts Are Bullish on Top Healthcare Picks
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Dow Jones  ·  06-17
Phathom Pharmaceuticals Price Target Maintained With a $26.00/Share by HC Wainwright & Co.
Needham pharmaceuticals analysts hold analyst/industry conference call
TIPRANKS  ·  05-27
Needham pharmaceuticals analysts hold analyst/industry conference call
Phathom Pharma to present at Jefferies Global Healthcare Conference
Reuters  ·  05-22
Phathom Pharma to present at Jefferies Global Healthcare Conference
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  05-22
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting
Reuters  ·  05-22
Phathom Pharmaceuticals shareholders elected Class I directors at annual meeting
Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026
Reuters  ·  05-20
Phathom presents Phase 3 pHalcon-NERD-301 vonoprazan symptom analysis at DDW 2026
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
GlobeNewswire  ·  05-20
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss
Simply Wall St.  ·  05-09
Phathom (PHAT) Is Up 9.4% After Reaffirming 2026 Profitability Timeline And Narrowing Q1 Loss
Phathom to highlight VOQUEZNA at DDW annual meeting
Reuters  ·  05-01
Phathom to highlight VOQUEZNA at DDW annual meeting
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)
TIPRANKS  ·  05-01
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)

Introduction

Company Name.
Phathom Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Issue price:
--